EventsAntibiotics 2026—Advances in Antimicrobial Action and Resistance
Published
This submission belongs to the session S4. Conventional and Novel Approaches in the Discovery of New Antimicrobial Agents of the event Antibiotics 2026—Advances in Antimicrobial Action and Resistance
Published date
04 May, 2026
Academic Editor
author-avatarMarc Maresca
Citation
Zeina Khattab, Dhai Ibrahim, Sama S. Eltaher, Mohamed Elhadidy, Natural compounds Interactions and Sequential Quercetin–Ciprofloxacin Application as Non-Bactericidal Strategies against MRSA Biofilms, in Proceedings of Antibiotics 2026—Advances in Antimicrobial Action and Resistance, Barcelona, 11 May–14 May 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Natural compounds Interactions and Sequential Quercetin–Ciprofloxacin Application as Non-Bactericidal Strategies against MRSA Biofilms

Dhai Ibrahim 1,2
Sama S. Eltaher 1,2
1. Center for Genomics, Helmy Institute for Medical Sciences, Zewail City of Science and Technology, Giza, Egypt, Egypt
2. Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt
Abstract

Staphylococcus aureus (S. aureus) is a major global health concern and is classified by the World Health Organization (WHO) as a high-priority pathogen due to its multidrug-resistant (MDR) profile and virulence. Biofilm formation is a critical resistance mechanism, enhancing bacterial tolerance to antimicrobials up to 1000-fold. Consequently, the development of anti-biofilm therapies represents an urgent need, providing an alternative to conventional bactericidal antibiotics. Natural compounds, owing to their diverse modes of action and low resistance potential, have emerged as promising candidates. This study evaluates the antibacterial and antibiofilm activities of baicalin, quercetin, and 18β-glycyrrhetinic acid—individually and in combination—against methicillin-resistant S. aureus (MRSA) isolates. A panel of community-associated MRSA (CA-MRSA) isolates was subjected to microbiological assays, assessing effects on bacterial growth, biofilm inhibition, and biofilm eradication. Combination studies were further performed; including sequential models with thymoquinone and ciprofloxacin to assess synergistic effects. None of the tested compounds exhibited strong bactericidal activity against planktonic MRSA cells. However, baicalin and quercetin showed notable biofilm inhibition, whereas 18β- glycyrrhetinic acid demonstrated minimal effect. Quercetin exhibited a potent and dose-dependent antibiofilm activity. Combination assays revealed that quercetin–baicalin and quercetin–18β-glycyrrhetinic acid pairings produced additive inhibitory effects across MRSA strains. In contrast, the quercetin–thymoquinone combination displayed antagonistic behavior, possibly due to overlapping mechanisms of action. None of the tested compounds significantly eradicated pre-formed biofilms. The sequential treatment of an inhibitor followed by an eradicating agent has shown significant biofilm reduction in comparison to that of each compound solely. These findings demonstrate that natural compounds, particularly quercetin-based combinations, can effectively inhibit MRSA biofilm formation through non-bactericidal mechanisms. Such approaches may reduce selective pressure for resistance and offer complementary strategies to existing antibiotics. Future research should focus on elucidating molecular mechanisms of action and improving compound bioavailability and delivery to advance the translational potential of natural anti-biofilm therapies.

Keywords
Staphylococcus aureus
Biofilm inhibition
Antimicrobial resistance
non-bactericidal therapy
Antimicrobial resistance, virulence and genetic diversity of Escherichia coli from a hospital food service
China's response to antimicrobial resistance governance practices, 2017-2024: a systematic gap analysis based on artificial intelligence